ASH Data Drive Momentum For Revolution In CLL Treatment

American Society of Hematology meeting provided a platform for J&J/AbbVie’s Imbruvica to continue on its strong upward trajectory and for AbbVie/Roche’s newcomer venetoclax to shine, while Gilead’s flagging Zydelig demonstrated mixed results.